---
schema_version: "secwatch.filing_event.v1"
accession: "0000014272-24-000094"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:47:43.059875+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bristol-Myers Squibb Q1 revenue up 5% to $11.9B; GAAP loss per share $5.89 on acquired IPRD charges

## Summary
- Q1 revenues $11,865M (+5% reported, +6% ex-FX); growth portfolio revenues $4,767M (+8%, +11% ex-FX).
- GAAP loss per share ($5.89); Non-GAAP loss per share ($4.40); includes $6.30/share impact from acquired IPRD and licensing.
- Completed acquisitions of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune collaboration.
- Announced strategic productivity initiative targeting ~$1.5B in cost savings, majority reinvested for innovation.
- Updated 2024 non-GAAP EPS and line-item guidance to reflect recent transactions; Abecma and Breyanzi received new U.S. approvals.

## SEC filing metadata
- accession: 0000014272-24-000094
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000001427224000094/0000014272-24-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000001427224000094/bmy-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000014272-24-000094
- JSON: https://secwatch.observer/filing/0000014272-24-000094.json
- Plain text: https://secwatch.observer/filing/0000014272-24-000094.txt

## Key facts
- Earnings Releases
  BRISTOL MYERS SQUIBB CO reported the first quarter of 2024 results: revenue $11,865, EPS (5.89).
  - Period: the first quarter of 2024
  - Revenue: $11,865
  - EPS: (5.89)
  - Result: reported results
  source text: get the most promising medicines to patients as quickly as possible." 1 First Quarter $ in millions, except per share amounts 2024 2023 Change Change Excl. F/X** Total Revenues $11,865 $11,337 5 % 6 % (Loss)/Earnings Per Share — GAAP* (5.89) 1.07 N/A N/A (Loss)/Earnings Per Share — Non-GAAP* ** (4.40) 2.05 N/A N/A Acquired IPRD charge and Licensing Income Net
  evidence_url: https://www.sec.gov/Archives/edgar/data/14272/000001427224000094/0000014272-24-000094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.